Filing Flows › Korro Bio (KRRO) › Q4 2025
Korro Bio (KRRO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 12, 2026
Korro Bio (KRRO) reported revenue of $1.3M for the fourth quarter 2025 (Q4 2025), -43% from a year earlier and +19% from the quarter before.
Korro Bio, Q4 2025: revenue $1.3M (-43% year over year), net loss $50.0M, operating cash flow −$17.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | +19% | -43% |
| Operating profit | −$50.4M | — | — |
| Net earnings | −$50.0M | — | — |
| Operating cash flow | −$17.7M | — | — |
What changed
Revenue was $1.3M in Q4 2025, down 43% year over year and up 19% from the previous quarter.
Operating costs exceeded revenue by $50.4M, an operating margin of -3900.6%. Total costs grew 104% against a revenue fall of 43%. The quarter ended with a net loss of $50.0M, wider than the previous quarter's $18.1M loss.
Operating cash flow was −$17.7M. Non-cash charges added back $649K of depreciation and $2.1M of share-based compensation. Working capital and other items added $29.6M. Capital expenditures of $84K exceeded it, leaving free cash flow of −$17.8M.
Questions
What was Korro Bio's revenue in the fourth quarter 2025?
Korro Bio (KRRO) reported revenue of $1.3M for the fourth quarter 2025 (Q4 2025), -43% from a year earlier and +19% from the quarter before.
Source: Korro Bio 10-K on SEC EDGAR.